Russell Investments Group Ltd. Has $85.44 Million Position in Celgene Co. (CELG)

Russell Investments Group Ltd. trimmed its position in Celgene Co. (NASDAQ:CELG) by 8.7% during the third quarter, Holdings Channel reports. The institutional investor owned 586,007 shares of the biopharmaceutical company’s stock after selling 55,690 shares during the period. Russell Investments Group Ltd.’s holdings in Celgene were worth $85,440,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently bought and sold shares of the stock. Grisanti Capital Management LLC purchased a new stake in shares of Celgene during the 2nd quarter worth $3,616,000. RiverPoint Capital Management LLC boosted its position in shares of Celgene by 3.1% during the 2nd quarter. RiverPoint Capital Management LLC now owns 121,654 shares of the biopharmaceutical company’s stock worth $15,799,000 after purchasing an additional 3,680 shares in the last quarter. LSV Asset Management purchased a new stake in shares of Celgene during the 2nd quarter worth $1,701,000. Spectrum Management Group Inc. purchased a new stake in shares of Celgene during the 2nd quarter worth $462,000. Finally, Polen Capital Management LLC boosted its position in shares of Celgene by 7.7% during the 2nd quarter. Polen Capital Management LLC now owns 5,082,991 shares of the biopharmaceutical company’s stock worth $660,128,000 after purchasing an additional 363,108 shares in the last quarter. Hedge funds and other institutional investors own 79.74% of the company’s stock.

Several equities research analysts have commented on CELG shares. BMO Capital Markets boosted their target price on shares of Celgene from $148.00 to $155.00 and gave the stock an “outperform” rating in a research report on Friday, November 17th. Oppenheimer restated a “buy” rating and set a $170.00 target price on shares of Celgene in a research report on Friday, October 20th. Vetr upgraded shares of Celgene from a “buy” rating to a “strong-buy” rating and set a $144.39 target price on the stock in a research report on Monday, October 23rd. Cann restated a “buy” rating on shares of Celgene in a research report on Thursday, October 26th. Finally, Morgan Stanley upgraded shares of Celgene from an “underweight” rating to an “equal weight” rating in a research report on Friday, October 27th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and nineteen have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $131.18.

Celgene Co. (CELG) opened at $106.00 on Friday. Celgene Co. has a one year low of $94.55 and a one year high of $147.17. The firm has a market cap of $83,455.60, a PE ratio of 25.18, a P/E/G ratio of 0.68 and a beta of 1.77. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31.

Celgene (NASDAQ:CELG) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, beating the consensus estimate of $1.87 by $0.04. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The firm had revenue of $3.29 billion during the quarter, compared to the consensus estimate of $3.42 billion. During the same quarter in the previous year, the company posted $1.58 EPS. The firm’s revenue for the quarter was up 10.2% on a year-over-year basis. equities analysts expect that Celgene Co. will post 6.69 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://www.com-unik.info/2018/01/14/russell-investments-group-ltd-has-85-44-million-position-in-celgene-co-celg.html.

Celgene Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit